Diabetes Mellitus Flashcards
1
Q
Diabetes Mellitus (DM)
A
A multisystem disease related to abnormal insulin production, impaired insulin utilization, or both.
2
Q
Diabetic ketoacidosis (DKA)
A
An acute metabolic complication of diabetes occurring when fats are metabolized in the absence of insulin; characterized by hyperglycemia, ketosis, acidosis, and dehydration.
3
Q
Diabetic Nephropathy
A
A microvascular complication of diabetes mellitus associated with damage to the small blood vessels that supply the glomeruli of the kidney.
4
Q
Diabetic Neuropathy
A
Nerve damage that occurs because of the metabolic derangements associated with diabetes mellitus.
5
Q
Glycemic Index (GI)
A
The rise in blood glucose levels after a person has consumed a carbohydrate-containing food.
6
Q
Hyperosmolar hyperglycemic state (HHS)
A
A life-threatening syndrome that can occur in the patient with diabetes who is able to produce enough insulin to prevent diabetic ketoacidosis but not enough to prevent severe hyperglycemia, osmotic diuresis, and extracellular fluid depletion.
7
Q
Insulin Resistance
A
A condition in which body tissues do not respond to the action of insulin
8
Q
Lipodystrophy
A
Hypertrophy or atrophy of subcutaneous tissue.
9
Q
Prediabetes
A
When a fasting or a 2-hour plasma glucose level is higher than normal but lower than that considered diagnostic for diabetes; places the individual at risk for developing diabetes and its complications. Also known as impaired glucose tolerance (IGT) or impaired fasting glucose (IFG).
10
Q
Somogyi Effect
A
Produces a decline in blood glucose level in response to too much insulin; counter-regulatory hormones are released that cause rebound hyperglycemia and ketosis resulting in high blood glucose levels at morning testing; treatment is a reduction of insulin dosage.
11
Q
Onset of type 1 DM
A
- < 30 years old
- Peak onset about 11-13 years old
- Long preclinical period, then rapid symptom onset, often emergent (i.e. –DKA)
12
Q
Insulin is produced by
A
the beta cells of the islets of Langerhans in the pancrea
13
Q
Basal rate
A
Insulin is produced in continuous small amounts
14
Q
average insulin rate
A
40-50 u/day
15
Q
Normal blood sugar ranges
A
4-6 mmol/L
16
Q
Hormones that work to increase glucose by opposing insulin (counterregulatory)
A
Glucagon, epinephrine, growth hormone, cortisol
17
Q
How do counterregulatory hormones oppose insulin
A
Stimulate glucose production and output by the liver and decreasing the movement of glucose into the cells
18
Q
Etiology of DM1
A
- Autoimmune – autoantibodies in the islet cells cause a
- 80-90% reduction in normal beta cell function
genetic predisposition (HLAs) - viral trigger causing beta cell destruction
19
Q
When do clinical manifestations occur in DM1
A
when the pancreas can no longer
produce insulin
20
Q
When do clinical manifestations occur in DM1
A
when the pancreas can no longer
produce insulin
21
Q
Clinical Manifestations of DM1
A
sudden weight loss
Polydipsia – excessive thirst
Polyphagia – excessive hunger
Polyuria – frequent urination
22
Q
Cause of Polyuria and polydipsia
A
secondary to the osmotic effect of hyperglycemia (water is pulled out of the ICF, causing cellular dehydration)
23
Q
Cause of polyphagia
A
secondary cellular malnourishment – without insulin, the cells cannot use glucose for energy
24
Q
Cause of weight loss in DM1
A
a body cannot use glucose, so it uses body
fat and protein
25
Cause of weakness and fatigue in DM1
d/t lack of glucose for energy
26
Sequela of hyperglycemia
changes to visual acuity, increased infections, delayed healing
27
non-insulin dependent diabetes
Type 2 diabetes mellitus
28
Pre-diabetes
aka ‘ impaired glucose tolerance’ (IGT) or impaired fasting glucose’ (IFG)
Lower blood glucose than diabetes
29
‘impaired glucose tolerance’ (IGT) blood glucose
7.1-11.0 mmol/L
30
'impaired fasting glucose’ (IFG) blood glucose
6.1-6.9 mmol/L
31
Treatment of pre-diabetes
- Monitoring of blood glucose level and HgbA1C
- Maintaining healthy body weight, regular exercise, healthy diet
- Some medications may be indicated
32
What percentage of people with prediabetes progress to being diagnosed with diabetes?
25% within 3-5 years
33
Onset of type 2 diabetes
- Onset > 35 years old
- Gradual onset, many years with asymptomatic hyperglycemia
- Progressive disease – even with perfect glycemic control and lifestyle modifications
34
What is the most prevalent type of diabetes?
90% of diabetes is type II
35
Risk factors for type 2 diabetes
- High BMI: > 25 – overweight > 30 - obese
- 80-90% of type II DM are overweight at the time of diagnosis
- Aboriginal, Hispanic, South Asian, African ancestry
- Insulin resistance (HTN, dyslipidemia, overweight,
abdominal obesity – apple shape – PCOS)
- History of IGT (impaired glucose tolerance) or IFG
(impaired fasting glucose)
- History of gestational diabetes and delivery of
macrosomic infant
- History of bipolar disorders (d/t medications)
36
Medications that Increase Blood Glucose:
- Certain medicines to treat schizophrenia and psychosis
- Beta-blockers
- Corticosteroids
- Estrogens
- Lithium
- Oral contraceptives
- Phenytoin
- Salicylates
- Thiazide diuretics
- Tricyclic antidepressants
37
What does insulin do?
lowers blood glucose by increasing the transportation of glucose into cells and promotes conversion of glucose to glycogen; also promotes conversion of amino acids to protein in muscles.
38
Type II Diabetes
Pancreas produces some insulin BUT it may not be
enough insulin and/or the insulin may be poorly utilized
by the body tissues
39
4 Metabolic Abnormalities Contribute to type II diabetes
1. Insulin Resistance (major factor)
2. Beta Cell Fatigue (major factor)
3. Inappropriate glucose production by liver (minor factor)
4. Altered hormone/cytokine production in adipose tissue (minor factor?)
40
Insulin Resistance in Type 11 diabetes
- Unresponsive and/or low numbers of insulin receptors
(mostly fat, skeletal muscle, liver cells)
- Results in glucose not entering cells and hyperglycemia
- In early type II DM: pancreas responds to this hyperglycemia by producing ++ insulin (in the presence of normal beta cell function), resulting to hyperinsulinemia
41
Beta Cell Fatigue in Type II diabetes
- Due to the hyperinsulinemia!
- Results in IFG and IGT (Prediabetes) – can be corrected back to euglycemic states with lifestyle modifications and sometimes meds
42
Inappropriate glucose production by liver in type II diabetes
Poor regulation, in proper response
43
Altered hormone/cytokine production in adipose
| tissue in type II diabetes
Adipokines (adiponectin and leptin) – role in glucose and fat metabolism – contribute to type II DM
44
Metabolic Syndrome
Cluster of abnormalities that synergistically increase the risk for CVD
45
Risk factors for metabolic syndrome
```
central obesity (apple shape); sedentary
lifestyle; urbanization/Westernization; Aboriginal, Hispanic, African ancestry, Abdominal obesity, HTN, dyslipidemia, insulin resistance, dysglycemia
```
46
Metabolic syndrome results in what?
significant risk for development of type II DM
47
Clinical Manifestations of Type II diabetes
- Symptoms often nonspecific
- Sometimes similar to Type I (3 P’s)
- More commonly: fatigue, recurrent infections, prolonged wound healing, changes in visual acuity, peripheral neuropathy
48
Age of onset Type I vs. Type II Diabetes
Type I Diabetes: <30yo; peaks at 11-30
| Type II Diabetes: >35yo
49
Type of onset Type I vs. Type II Diabetes
Type I Diabetes: Rapis onset
| Type II Diabetes: Gradual onset
50
Prevalence Type I vs. Type II Diabetes
Type I Diabetes: 5-10%
| Type II Diabetes: 90%
51
Environmental Factors Type I vs. Type II Diabetes
Type I Diabetes: Virus; toxins
Type II Diabetes: Insulin resistance, decreased insulin
production, altered adipokin production
52
Islet-Cell Antibodies Type I vs. Type II Diabetes
Type I Diabetes: Often present at onset
| Type II Diabetes: None
53
Endogenous Insulin Type I vs. Type II Diabetes
Type I Diabetes: Minimal or absent
| Type II Diabetes: Possibly excessive, reduced utilization, diminishes over time
54
Nutritional Status Type I vs. Type II Diabetes
Type I Diabetes: Thin, catabolic state
| Type II Diabetes: Obese or normal
55
Symptoms Type I vs. Type II Diabetes
Type I Diabetes: 3 P’s and fatigue
Type II Diabetes: Often none, fatigue, recurrent
infection + 3 P's
56
Ketosis Type I vs. Type II Diabetes
Type I Diabetes: Prone at onset or during insulin deficiency
| Type II Diabetes: Resistant except infection or stress
57
Nutritional Therapy Type I vs. Type II Diabetes
Type I Diabetes: Essential
| Type II Diabetes: Essential
58
Insulin Type I vs. Type II Diabetes
Type I Diabetes: Required for all
| Type II Diabetes: Required for some
59
Oral Hyperglycemic Agents Type I vs. Type II Diabetes
Type I Diabetes: Not Indicated
| Type II Diabetes: Often Beneficial
60
Vascular and neurological complications Type I vs. Type II Diabetes
Type I Diabetes: Frequent
| Type II Diabetes: Frequent
61
Type II diabetes diagnostic studies
Three methods of diagnosis; must be confirmed with
additional test (any method) on another day
1. Fasting glucose > 7 mmol/L
2. Random glucose ≥11.1 mmol/L plus symptoms
3. Two hour OGTT (oral glucose tolerance test) with 75 g glucose load
62
Glycosylated Hemoglobin
- aka HgbA1C
- Determines glycemic control over time
- Last three months (really last 6-8/52); usually assessed q3/12
- Test shows the amount of glucose that has been attached to Hgb molecules
- Target: 7% - lower is not better, demonstrates increased risk of CV events
- For older adults – should match their age i.e. – 80 y.o.
should be 8% - if too low increases risk for hypoglycemia
63
Goals of collaborative care for type II diabetes
- Glycemic control:
~ Fasting blood sugar 4-7 mmol/L
~ Post prandial 5-10 mmol/L (within 1-2h after meals)
- Prevent acute and chronic complications
- Empower patients via education to promote self-management of disease
64
Team members involved in care of DMII
- Primary care practitioner
- Diabetic educator
- Dietitian
- Pharmacist
- Endocrinologist
65
Nutritional Therapy in DM
- Cornerstone of DM therapy
- Education essential
- Although labeled a diabetic diet – truly, it is just a healthy diet we should all be eating
66
Highlights of nutritional therapy for DM
- Three meals per day at regular times, no longer than 6 hours apart
- Limit sugar (pop, dessert, candy, jam, honey)
- Limit high-fat foods
- Eat more high-fiber foods
- Drink water
- Add physical activity
67
Type I Nutritional Therapy
Meals based on preferred foods and balanced with insulin and exercise pattern
68
Type II Nutritional Therapy
- 80-90% of type II DM are overweight
- Nutritional therapy is focused on glucose, lipid, BP control and weight loss
- Weight loss of 5-7% of body weight improves glycemic control
69
Alcohol considerations in Diabetes
- High calories, no nutritive value, contributes to increased triglycerides
- High risk for hypoglycemia, may be delayed in type I by up to 24 h
- 1-2 drinks per day or <14/wk for men and <9/wk for women
- Decreased risk for hypoglycemia by having drink with food
70
Evaluation of Nutritional Therapy
- lab work – HgbA1C, lipid profile, eGFR urine ACR
- Blood pressure
- Body weight, BMI, waist circumference
71
Benefits of exercise for diabetic patients
- Once again – not just for diabetics!
- Great way to burn off excess sugar
- ↑ insulin sensitivity = ↓blood glucose
- Contributes to weight loss
- ↓need for diabetic medicines
- ↓triglycerides and LDL and ↑ HDL
- ↓ blood pressure and improves circulation
72
How much exercise should someone with Type II diabetes be getting after medical clearance?
Type II 150 min/week over at least three sessions – only counts if
you sweat, should include weight bearing exercise
73
Risk of exercise in person with diabetes
↑risk for hypoglycemia if on medications that can cause
| hypoglycemia
74
How to prevent hypoglycemia after exercise?
time 1 h after meals, or have a snack prior to exercise; carry fast-acting sugar
75
How to evaluate for symptoms and titration of
| medicines?
Blood glucose monitoring
76
Fasting Glucose Target Value
4-7 mmol/L
77
Post Prandial (1-2 hours after meals) Target Values
5-10 mmol/L
78
Indication of Insulin in Type I diabetes
Required from diagnosis
79
Indication of Insulin in Type II diabetes
1. Required when lifestyle modifications (diet, exercise)
and oral anti-hyperglycemics are inadequate for
glycemic control.
2. Required when HgbA1c is markedly increased at
diagnosis.
3. Required with acute episodic health challenges –
increased stress, illness, infection = hyperglycemia; also
may not be able to tolerate usual oral medications d/t
nature of illness, surgery etc.
80
Classifications of insulin
```
Rapid
short
intermediate
long
mixes
```
81
Long-Acting (Basal) Background Insulin
- i.e. - Lantus and Levemir
- extended long-acting insulin with steady release over 24 h period
- no peak; ↓↓ risk of hypoglycemia
- OD administration; cannot be mixed with any other
insulin
82
Intermediate–Acting (Basal) Insulin
- i.e. NPH
- More often administered BID, total daily dose divided 2/3 with BF and 1/3 with supper
- Often used in combination with mealtime insulin
83
Mealtime Insulin (Bolus)
- i.e. – Humalog and Novorapid
- Onset of action 10-15min
- Best mimics natural insulin secretion r/t meals
- Give when food is insight
- Often used in combination with long or intermediate
acting insulin for more consistent glycemic control
- Titrated by glucose readings
- ALSO: Regular insulin – action 30-60 minutes, so
administration should be timed 30-35 min prior to meal
84
Insulin Mechanism of Action:
Substitute for endogenous insulin; allows for metabolism of carbohydrates, fats, and proteins; for the storage of insulin in the liver, and conversion of glycogen to fat stores
85
Insulin Contraindications
Allergy; hypoglycemia
86
Insulin Adverse Reactions
Hypoglycemia (d/t too much insulin!); also tachycardia,
palpitations, headache, lethargy, tremors, weakness, fatigue, delirium, sweating, blurred vision, dry mouth, hunger, nausea, flushing, rash, urticaria, anaphylaxis
87
Insulin Interactions
Numerous drug-drug that result in hypo or hyperglycemia
88
Insulin Allergic Reaction
- Generally local – erythema, pruritus at injection site
- Self-limiting – first 1-3 months of therapy
- Low dose antihistamine
- True anaphylaxis or urticaria very rare - r/t use of animal insulins
89
Lipodystrophy
- Hypertrophy or atrophy of SC tissue at injection sites
- d/t using the same site repeatedly
- Thickening of tissues = inconsistent absorption
- Mostly with animal insulins
90
Somogyi Effect
- Characterized by wide difference in early morning low and fasting high glucose levels
- Generally occurs during hours of sleep
} First, decline in blood glucose in response to too much insulin
- Second, counter-regulatory hormones stimulates lipolysis,
gluconeogenesis, glycogenolysis – result: rebound
hyperglycemia and ketosis
- PROBLEMATIC! Morning glucose readings are high so MORE INSULIN gets administered
91
Somogyi Effect Manifestations:
headache, nightmares, night sweats
92
Somogyi Effect Treatment
checking blood glucose between 0200-0400h,
| titrate insulin accordingly (reduce hs insulin, ensure bedtime snack, monitor ETOH use)
93
Dawn Phenomenon
Hyperglycemia upon waking d/t the release of counterregulatory hormones in the predawn hours (body’s normal way to kick your behind out of bed!)
94
Dawn Phenomenon Contributory Factors
– cortisol and growth hormones
| - Affects most people with DM, esp. when growth hormone is at its peak in adolescence and young adulthood
95
Dawn Phenomenon Treatment
checking blood glucose between 0200-0400h
| (make sure this is not Somogyi effect); increase insulin dose, monitor diet, quality/quantity of hs snack
96
Acute complications of DM
- Hypoglycemia
- Diabetic Ketoacidosis (DKA)
- Hyperosmolar Hyperglycemic Nonketotic Syndrome (HHS)
97
Chronic complications of DM
```
Microvascular:
- Retinopathy
- Nephropathy
- Neuropathy (Peripheral and Autonomic)
Macrovascular:
- Atherosclerosis (CAD, PAD)
ALSO:
- Foot Complications
- Integumentary Complications
- Infection
```
98
Target fasting blood glucose
4-7 mmol/L
99
Target postprandial (1-2 hours pc meals)
5-10 mmol/L
100
Hypoglycemia
Occurs when too much insulin vs. glucose
| Low Blood glucose
101
Hypoglycemia Objective assessment
blood glucose < 4 mmol/L
102
Hypoglycemia Subjective assessment
individual symptoms of hypoglycemia vary
| - some people tolerate lower sugars better, other not so much
103
Causes of Hypoglycemia
- Too much insulin (also occurs with oral antihyperglycemics)
- Not enough food (meals to small or omitted)
- Mismatch in timing of insulin administration and food intake
- Excessive exercise
- Medication side effects
- Weight loss without adjustment of diabetic medications
- ETOH intake without food
104
Signs and symptoms of hypoglycemia
- Cold clammy skin
- Numbness fingers, toes, mouth
- Rapid heartbeat
- Emotional changes
- Nightmares, disrupted sleep
- Headache
- Nervousness, tremors
- Faintness, dizziness
- Unsteady gait, slurred speech
- Hunger
- Vision changes
- Seizures, coma
105
Treatment of Hypoglycemia
- Test blood sugar if able
- 15-20g of simple carbohydrates and repeat blood sugar in 15 minutes – what is the target value?
- Repeat until relief obtained
- If meal is > 1 hour away snack of starch and protein
(cheese and crackers, cereal and milk, PB sandwich)
- Avoid overtreatment to prevent rebound hyperglycemia
106
Examples of Simple Carbohydrates:
- Juice box
- Glucose tabs
- ½ roll of lifesavers
- Hard candies
- Cake icing tubes
NOT:
- Cupcakes, cookies, ice cream (fat delays absorption of glucose)
107
Prevention Focused Education
- S & S of hypoglycemia
- Treatment of hypoglycemia (at home and away)
- Education of family, friends, coworkers re: hypoglycemia
- Review recent blood sugar readings (look for patterns and changes)
- Review medication regimen (dose vs. food, insulin
administration)
- Review diet, use of food diary, importance of snacks
- Review compensation for exercise
108
Treatment of Hypoglycemia in hospital
- Follow facility hypoglycemic protocol
- 15-20g of simple carbohydrates and repeat blood sugar in 15 minutes
- Repeat until relief obtained
- Use pudding/baby food for patients with dysphagia
- Glucagon I mg IM/SC (hepatic response, converts glycogen to glucose; can result in rebound hypoglycemia)
- Dextrose 50% via IV infusion
109
Follow up of hypoglycemia
- Document, notify MRP as per facility protocol
- Generally, adjustment of medication regimen is made
- Blood sugar target may be adjusted to decrease risk of hypoglycemia in high-risk populations (older adults,
brittle diabetics)
110
```
Diabetic Ketoacidosis (DKA)
aka diabetic acidosis or diabetic coma
```
- No insulin so body metabolizes fats instead
- Characterized by hyperglycemia, ketosis, acidosis, and dehydration
- More common in type I; also in type II with severe
illness/stress
111
Contributing factors of Diabetic Ketoacidosis (DKA)
- Illness (esp. with dehydration, N/V)
- Infection
- Inadequate insulin, insulin omission
- Undiagnosed type I DM (often presenting episode)
- Poor self-management
- Change in diet, medications, exercise
112
Pathophysiology of Diabetic Ketoacidosis (DKA)
- No insulin means glucose can not be used for fuel
- Body uses fat for fuel – acidic by-product of fat metabolism is ketones
- Ketones alters body’s pH balance – metabolic acidosis
- Ketonuria – ketone bodies secreted in urine; cations also excreted in an effort to maintain electrical neutrality
113
Is Diabetic Ketoacidosis (DKA) a medical emergency
YES!
114
What does lack of insulin do?
- Impairs protein synthesis and ++ protein degradation = nitrogen loss from tissues
- Stimulates production from amino acid (from protein) in liver – compounds hyperglycemia
- Hyperglycemia causes osmotic diuresis – depletes Na, K, Mg, PO4
115
How does Diabetic Ketoacidosis (DKA) lead to death?
- Acidosis causes N & V and more fluid and lyte loss
- Progresses to hypovolemia and shock
- Hypovolemic shock = acute renal failure (ARF) – causes retention of ketones and glucose and progresses metabolic acidosis
- Untreated – comatose d/t dehydration, lyte imbalance and acidosis - DEATH
116
Clinical manifestations of Diabetic Ketoacidosis (DKA)
- Early – lethargy and weakness
- Polyuria and polydipsia – contribute to dehydration
- Dehydration: poor skin turgor, dry mucous membranes, tachycardia, pulse weak, orthostatic hypotension; skin dry and flushed, eyes sunken, fever
- Nausea, vomiting, abd pain
- Oral or vaginal candida albicans (yeast infection)
- Restlessness, confusion
- Kussmaul’s Respirations (rapid, deep, breathing with dyspnea
- Acetone breath – sweet, fruity odour
- Hyperglycemia
- ABG’s – ph < 7.35 HC03 < 15 mmol/L
- Ketones in blood and urine
117
Emergency Management of Diabetic Ketoacidosis (DKA)
- ABC’s – ensure patent airway, O2 prn
- Establish IV access for:
- Fluid resuscitation - what solution and why?
- Goal to increase urine output to _______ mL/H
- IV insulin bolus followed by infusion
- IV KCL to prevent/correct hypokalemia (K+ may be
normal but with insulin administration K+ will shift
into cells)
- IV NaHCO3 for severe acidosis (<7 mmol/H)
118
Nursing Interventions for Diabetic Ketoacidosis (DKA)
- Establish diabetic history, last dose of insulin, last PO
intake
- Monitor VS and SpO2, LOC, cardiac rhythm (ECG
monitoring)
- Monitor in & outs (fluid balance)
- Assess respiratory status
- Assess cardiovascular status
- Monitor serum glucose, electrolytes, and ABG’s
- Assess blood and urine for ketones
119
Hyperosmolar Hyperglycemic Nonketotic Syndrome (HHS) occurs when?
Occurs in diabetics who have enough insulin to prevent DKA, but not enough insulin to prevent severe
hyperglycemia, osmotic diuresis, and ECF depletion
120
Which is more common, HHS or DKA?
DKA
121
Primary difference between Hyperosmolar Hyperglycemic Nonketotic Syndrome (HHS) and Diabetic Ketoacidosis (DKA)
- Primary difference between DKA and HHS – enough
insulin to prevent ketoacidosis
- Has fewer symptoms, so hyperglycemia quite significant prior to recognition
122
Clinical Manifestations of Hyperosmolar Hyperglycemic Nonketotic Syndrome (HHS)
- Hyperglycemia causes increase in serum osmolarity,
causing severe neurological manifestations
- Somnolence, coma, seizures, hemiparesis, aphasia
- Commonly occurs in older adults with type II DM –
presenting as:
- impaired thirst and/or functional inability to replace
fluids
- History of inadequate fluid intake, mental
depression, polyuria
- Lab Work reveals: blood glucose > 23 mmol/L, increased serum osmolarity and minimal to no ketone bodies in serum/urine
123
Emergency Management of Hyperosmolar Hyperglycemic Nonketotic Syndrome (HHS)
- Similar to DKA
- IV administration of 0.9 % or 0.45 % NaCL
- Regular insulin via bolus followed by continuous infusion
- IV fluids changed when blood glucose about 14 mmol/L to prevent rebound hypoglycemia (what solution will they use?)
- Electrolytes monitored and replaced; K loss not as profound as in DKA
124
Nursing interventions of Hyperosmolar Hyperglycemic Nonketotic Syndrome (HHS)
- Monitor VS, blood glucose readings, laboratory values, in and outs (fluid balance), ECG monitoring
- Medication administration and IV therapy
- Assess neurovascular, cardiovascular, respiratory status
125
Macrovascular
large and medium sized vessels
126
Dislipidemia
- ↑LDL (bad cholesterol) – diet related
- ↓HDL (good cholesterol) – increases with exercise
- ↑ triglycerides - from diet high in sweets and ETOH
127
Dislipidemia can result in:
```
Cerebrovascular Disease (CVA)
Cardiovascular Disease (HTN, angina, MI),
Peripheral vascular disease (intermittent claudication, lower extremity amputation)
```
128
Macrovascular complications are further complicated
| by many modifiable lifestyle factors, such as:
- High BP
- Smoking
- Overweight
- High fat and cholesterol levels
- Sedentary lifestyle
129
Treatment of Macrovascular complications
- Routine Screening: BP (target <130-80 mmHg), serum
lipid profile
- Tight glycemic control (HgbA1c <7)
- Lifestyle modifications: low-fat diabetic diet, weight loss, exercise, ETOH in moderation, smoking cessation
- Low dose ASA
- Medications for dyslipidemia: statins, also fibrates, EFA’s like salmon oil capsules
130
Microvascular Complications
- Persistent hyperglycemia causes thickening of vessel
membranes in the capillaries and arterioles
- These complications are specific to DM
131
Three main microvascular complications
1. Eyes – retinopathy
2. Kidneys – nephropathy
3. Feet and lower extremities – neuropathy
132
Retinopathy
- Microvascular damage to the vessels of the retina from chronic hyperglycemia
- DM for 15 years: 100% in type I and 80% type II
- Most common cause of new-onset blindness in people of working age
133
Two types of retinopathy
Proliferative: more severe – risk of blindness 50 % with
no treatment
Non-Proliferative: more common – risk of blindness if macula involved
134
Proliferative Retinopathy
- retinal capillary occlusion result in new vessels being
formed, BUT these new vessels are ++ fragile and hemorrhage easily
- vessels tear and bleed – see ‘floaters’ black or red spots or lines
- can result in retinal tear or detachment (eye emergency!)
135
Non-proliferative Retinopathy
- partial occlusion of vessels causes microaneurysms in
capillary walls
- resulting in fluid leaking out and retinal edema,
progressing to exudates or intraretinal hemorrhage
136
Collaborative Interventions of retinopathy
- Prevention!
| - Annual dilated eye exam by ophthalmologist
137
Treatment of retinopathy
1. Photocoagulation
2. Cryotherapy
3. Vitrectomy
138
Photocoagulation
laser destruction of ischemic areas of retina to prevent the formation of new fragile vessels
139
Cryotherapy
for peripheral retina that cannot be reached
| by laser; topical anesthetic and freezing of trouble spots
140
Vitrectomy
aspiration of blood, membrane, fibres from the eye via a small incision just behind the cornea
141
Nephropathy in Diabetes
- Microvascular damage to the small blood vessel that
supply the glomeruli of the kidney
- Leading cause of end-stage kidney disease
- Similar risk regardless of type of diabetes
142
Risk factors for nephropathy
- HTN
- Genetic predisposition
- Smoking
- Chronic hyperglycemia
143
Treatment of nephropathy
- Routine screening: urine for ACR (albumin-creatinine
ratio); serum for eGFR, creatinine
- Tight glycemic control (HgbA1c <7)
- Lifestyle modifications: weight loss, exercise, smoking
cessation, ETOH in moderation
- Aggressive management of HTN: target BP < 120/70; ACE or ARB (even in absence of HTN d/t renal protective properties that prevent progression of nephropathy)
144
Neuropathy in diabetes
- Occurs in 60-70% of people with diabetes (= in both type I and II)
- Most commonly – peripheral sensory neuropathy – causes loss of protective sensation in feet and lower extremities – can result in lower limb amputation
- Also autonomic neuropathy – affects CNS
145
Etiology of Neuropathy
- Not well understood
- Theories include metabolic, vascular, and autoimmune
causation
- Most accepted theory– hyperglycemia
- Bathes nerves in sorbitol and fructose resulting in reduced nerve conduction and demyelination
- Contributes to ischemia that supply peripheral nerves
146
Sensory Neuropathy
- Most common – distal symmetrical neuropathy
- Affects the hands, the feet, or both
- aka ‘stocking-glove neuropathy’
147
Sensory Neuropathy Clinical Manifestations
- Paresthesias: tingling, burning, itching
- Pain: burning, cramping, crushing, tearing – worse at night, may only occur at night
- Loss of sensation: complete or partial
- Unable to determine hot or cold temperature
- Feeling of walking on pillows or numb feet
- Hyperesthesia – hyper-sensitive skin – bothered by light pressure i.e. – bed linen
- Atrophy of small muscle of hands or feet secondary to
neuropathy can cause deformity and limit ROM
148
Sensory Neuropathy Potential Risks
- LOPS – loss of protective sensation = foot ulcer or injury unknown to patient d/t lack of sensation
- Infection (cellulitis), amputation vs. poor wound healing
- Falls d/t lack of sensation, altered gait
- Limits activity level and tolerance
149
Treatment of Sensory Neuropathy
- Tight glycemic control
| - Prevention!
150
Medications for Sensory Neuropathy
- Topical creams (Capsaicin)
- TCA’s (Amitriptyline, Nortriptyline)
- SSRIs and SNRIs (i.e. – Effexor, Cymbalta)
- Anticonvulsants ( i.e. –Gabapentin, Lyrica)
151
Prevention Strategies for Sensory Neuropathy
10 point monofilament exam, tuning fork, checking pulses, skin inspection
152
Patient education for Sensory Neuropathy
- Wash feet daily and inspect; check water temperature
- Lotion application to prevent drying
- Avoid open-toed, open heel, high heel shoes
- Wear slippers to avoid injury
- Clean absorbent socks (cotton, wool); keep feet dry
- No heating pads or hot water bottles
- Trim nails evenly, no foot blades
- Go to diabetic foot care nurse
- Exercise, ROM, elevate, avoid crossing
153
Manifestations of Autonomic Neuropathy
- Hypoglycemic unawareness
GI
- Bowel incontinence and diarrhea
- Gastroparesis – delayed gastric emptying – can lead to anorexia, Nausea, vomiting, GERD, persistent fullness; can trigger hypoglycemia d/t delayed food absorption
GU
- Neurogenic bladder – decreased sensation of inner bladder wall – urinary retention (dysuria, weak stream)
- urinary incontinence
- ED(often first manifestation of autonomic failure); decreased libido; vaginitis
CVS
- Postural hypotension, resting tachycardia, silent MI
154
Most common cause of hospitalization for people with DM
Lower Extremity Complications
155
Lower Extremity Complications Multifactorial Etiology
- DM micro and macrovascular disease – LOPS –
injury/infection – amputation
- Sensory neuropathy
- Peripheral vascular disease (PVD)
- Poor glycemic control
- Smoking
- Clotting abnormalities
- Impaired immune function (delayed healing)
- Improper footwear, bare feet, stepping on foreign body common injury
156
Peripheral Vascular Disease (PVD)
- Reduced blood flow to lower extremities
- Decreased oxygen, WBC’s, vital nutrients
- Delayed wound healing and increased infection
- DM: blood is more viscous
157
Clinical Manifestations of Peripheral Vascular Disease (PVD)
- Intermittent claudication (pain with walking)
- Pain at rest, dependent rubor
- Cold feet, loss of hair
- Delayed cap refill
158
Treatment of Peripheral Vascular Disease (PVD)
Reducing risk factors (tight glycemic control, smoking
| cessation, proactive foot care)
159
Oral Anti-Hyperglycemics
```
Biguanides
Sulfonylureas
Meglitinides
Thiazolidinediones
a–Glucosidase Inhibitors
Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
```
160
The only drug in the class Biguanide
Metformin (glucophage)
161
‘ the key to open cells so they can use glucose’
1. ↓ glucose production by the liver
2. ↓ intestinal absorption of glucose
3. ↑ insulin receptor sensitivity in liver, skeletal muscle, and adipose tissue = ↑ glucose uptake
162
Metformin is used in which type of diabetes?
Ty II Diabetes
163
Pros of Biguanide
- No weight gain
- No hypoglycemia – does not ↑ insulin secretion from
pancreas
- Improves lipid profile - ↑ glucose uptake = ↓ liver production of triglycerides and cholesterol
- Can be used in pre-diabetes, esp. if obese and IFG; can reduce risk of progression to type II DM by 30%
164
Cons of Biguanide
- Terrible GI side fx: diarrhea, cramping, bloating, nausea – usually self-limiting; give with food
- Risk for lactic acidosis and ARF: with radiological contrast with iodine; held prior to such exams; kidney function evaluated prior re-start of Metformin
165
Sulfonylureas; Examples and what does it do?
- e.g. – Diamicron (glicazide), DiaBeta (glyburide)
2nd generation
- ‘the anchor’ or oral therapy fro type II DM for 30+ years ‘squeeze the insulin out of the pancreas’
- ↑ beta cell insulin production from the pancreas (requires some beta cell function)
Also
- Enhances action of insulin = ↑glucose uptake
- Slows insulin degradation in liver
166
Cons of Sulfonylureas
- Hypoglycemia, esp. with renal impairment and older adults; also r/t drug interactions
- Decreased effectiveness with prolonged use (r/t beta cell function)
167
Two drugs in the class Meglitinides
GlucoNorm (repaglinide) & Starlix (nateglinide)
168
How do Meglitinides work?
- ↑ insulin production from pancreas
- Very similar action to sulfonylureas BUT faster action and excretion= ↓ r/f hypoglycemia
- Taken prior to meals
169
Pros of Meglitinides
- ↓hypoglycemia
| - Good for people with irregular mealtimes
170
Cons of Meglitinides
- Side fx: headache, weight gain, hypoglycemia, dizziness, joint pain,
- Drug interactions: ↑ r/f hypoglycemia and hyperglycemia
171
Exemplar Thiazolidinediones
aka insulin sensitizing drugs, glitazones,
- Actos (pioglitazone)
- Avandia (rosiglitazone)
172
Pros of Thiazolidinediones
- Improve insulin sensitivity, transport, and utilization at target tissues
- Stimulate peripheral glucose uptake
- ↓ glucose and triglyceride production in the liver
- Most effective for people with insulin resistance
173
Cons of Thiazolidinediones
- Moderate weight gain, edema, fluid retention, mild anemia (concerns re use in CHF)
- Concerns re: liver toxicity - LFTs monitored
174
What drug falls under the class a-Glucosidase Inhibitors, aka 'starch blockers'
Glucobay (Arcabos)
175
How do a-Glucosidase Inhibitors work? and other need to knows.
- Less commonly used
- Enzyme inhibitor – enzyme a-glucosidase found on brush border of small intestine
- Slows the absorption of carbohydrates (glucose!) in the small intestine
- Taken with first bite of main meals
- Lowers postprandial glucose; no impact on fasting hyperglycemia
176
Pros of a-Glucosidase Inhibitors
- Reduce the risk of progression to type II DM by 30%
| - No hypoglycemia or weight gain
177
Cons of a-Glucosidase Inhibitors
- GI side fx: flatulence, diarrhea, abd pain
- Hugh dose = ↑LFTs
- Drug interactions that cause hyperglycemia
178
Dipeptidyl Peptidase-4 (DPP-4) Inhibitor exemplar drug
Januvia (Sitagliptin)
179
How do Dipeptidyl Peptidase-4 (DPP-4) Inhibitor work?
- Inhibition of DPP-4 slows the inactivation of incretin
hormones
- Incretin increases the synthesis and release of insulin
from the pancreas
180
Pros of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor?
- Glucose dependent – only respond in the presence of
hyperglycemia – thus decreased hypoglycemia
- Absence of weight gain
